Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy
- 26 July 2025
- journal article
- other
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1406-1409
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationThe Lancet Haematology, 2024
- Ruxolitinib–ECP combination treatment for refractory severe chronic graft-versus-host diseaseBone Marrow Transplantation, 2020
- Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell levelBone Marrow Transplantation, 2020
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host DiseaseNew England Journal of Medicine, 2020
- EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessmentBone Marrow Transplantation, 2018
- “Best practice” for extracorporeal photopheresis in acute and chronic graft‐versus‐host disease by Societa’ Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centersTransfusion, 2017
- Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host DiseaseTransplantation, 2016
- A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related MortalityTransplantation and Cellular Therapy, 2015
- Extracorporeal photopheresis for the treatment of acute and chronic graft‐versus‐host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus processTransfusion, 2013
- The best endpoint for acute GVHD treatment trialsBlood, 2010